Answers are grounded in this paper and cite their sources.
This Viewpoint discusses the new US Food and Drug Administration (FDA) boxed warning for intravenous ferric carboxymaltose, how the warning does not go far enough in explaining the potential dangers, and the risks vs benefits of the drug’s use.
No takes yet. Share an insight, caveat, or question.
Al-Samkari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: